Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry

[1]  Mark G. Jones,et al.  Accuracy Of A Clinical Diagnosis Of Idiopathic Pulmonary Fibrosis: A Study Of 275 Pulmonologists From 54 Countries , 2017 .

[2]  F. Martinez,et al.  Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study , 2017, European Respiratory Journal.

[3]  W. Cooper,et al.  Health‐related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry , 2017, Respirology.

[4]  M. Ando,et al.  The St. George’s Respiratory Questionnaire as a prognostic factor in IPF , 2017, Respiratory Research.

[5]  S. Birring,et al.  Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen , 2016, Pneumologie.

[6]  K. Brown,et al.  Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis , 2016, Patient related outcome measures.

[7]  A. Warth,et al.  Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis , 2016, PloS one.

[8]  G. Raghu,et al.  Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. , 2016, Chest.

[9]  J. Beaumont,et al.  Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis , 2016, Lung.

[10]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis: a network meta-analysis , 2016, BMC Medicine.

[11]  T. Welte,et al.  Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry , 2015, European Respiratory Journal.

[12]  K. Brown,et al.  The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review , 2014, Health and Quality of Life Outcomes.

[13]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[14]  J. Yorke,et al.  Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA) , 2014, BMJ Open Respiratory Research.

[15]  K. Albright,et al.  A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis , 2014, BMJ Open Respiratory Research.

[16]  J. Behr,et al.  Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry , 2014, BMJ Open Respiratory Research.

[17]  M. Horton,et al.  Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. , 2013, Chest.

[18]  H. Collard,et al.  Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan , 2013, Annals of Internal Medicine.

[19]  I. Higginson,et al.  Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature , 2012, Thorax.

[20]  M. Kreuter,et al.  [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. , 2012, Deutsche medizinische Wochenschrift.

[21]  K. Anstrom,et al.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. , 2012, Respiratory medicine.

[22]  Joyce S Lee,et al.  A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.

[23]  S. Birring,et al.  The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire , 2012, Thorax.

[24]  T. Marras,et al.  Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. , 2011, Canadian respiratory journal.

[25]  P. Jones,et al.  Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire , 2010, Thorax.

[26]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[27]  Meilan K. Han,et al.  Gender influences Health-Related Quality of Life in IPF. , 2010, Respiratory medicine.

[28]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[29]  Zhen-hua Li,et al.  Cross‐sectional and longitudinal construct validity of the Saint George's Respiratory Questionnaire in patients with IPF , 2008, Respirology.

[30]  M. Neary,et al.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.

[31]  J. Norris,et al.  Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. , 2007, American journal of respiratory and critical care medicine.

[32]  J. M. Salge,et al.  Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[33]  R. Kaplan,et al.  Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. , 2005, Journal of cardiopulmonary rehabilitation.

[34]  Y. Kondoh,et al.  Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? , 2005, Respiratory medicine.

[35]  A. Ries,et al.  Minimally Clinically Important Difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale , 2005, COPD.

[36]  G. Raghu,et al.  Assessment of health-related quality of life in patients with interstitial lung disease. , 1999, Chest.

[37]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[38]  S. Birring,et al.  [German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire"]. , 2016, Pneumologie.

[39]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .

[40]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[41]  Shandra L. Protzko,et al.  AMERICAN THORACIC SOCIETY DOCUMENTS An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline , 2015 .

[42]  Shandra L. Protzko,et al.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary An Update of the 2011 Clinical Practice Guideline , 2015 .

[43]  A. Russell,et al.  Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. , 2011, Chest.

[44]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .